Optical Coherence Tomography Useful for Macular Edema 
Medscape
May 16, 2012 (Chicago, Illinois) ? In patients with diabetic macular edema, visual acuity (VA) correlates with the magnitude of change in central macular thickness (CMT). The strongest correlation with VA is the absolute (correlation coefficient, ...

 

United Kingdom Grants ILUVIEN(R) Marketing Authorization for the Treatment of ... 
MarketWatch (press release)
"ILUVIEN addresses a significant unmet need by offering potential relief to patients who suffer from chronic diabetic macular edema and are insufficiently responsive to available therapies," said Andrew Lotery, professor of Ophthalmology, University of ...
pSivida Corp. Announces United Kingdom Grants ILUVIEN® Marketing Authorization ... SunHerald.com
PSivida Says UK Grants ILUVIEN Marketing Authorization For Treating Chronic DME RTT News
Psivida, Alimera eye drug gets UK marketing nod Reuters UK

all 11 news articles » 

Ampio Awarded US and Canadian Patents that will Bolster the Commercialization ... 
MarketWatch (press release)
These initial patents cover the North American territories and multiple additional patents for using Optina(TM) for the treatment of macular edema and diabetic retinopathy are pending worldwide. According to Michael Macaluso, Ampio's CEO, "Optina(TM) ...
Ampio (AMPE) Gets US Patent for DME Drug Optina StreetInsider.com (subscription)

all 10 news articles » 

pSivida Corp. Announces ILUVIEN(R) Receives Marketing Authorization in Austria ... 
MarketWatch (press release)
ILUVIEN(R) for the treatment of Diabetic Macular Edema (DME), which is licensed to Alimera Sciences, Inc., is pSivida's most advanced product candidate, and based on a consensus arrived upon by the RMS and the CMS, the MHRA issued its Final Assessment ...
ILUVIEN(R) Receives Marketing Authorization in Austria for the Treatment of ... GlobeNewsWire (press release)
pSivida ILUVIEN gains marketing authorization in Austria Pharmaceutical Business Review

all 24 news articles » 

ILUVIEN(R) Receives Marketing Authorization in Austria for the Treatment of ... 
MarketWatch (press release)
"With the approval of ILUVIEN, Austrians who are suffering from chronic diabetic macular edema and unresponsive to current therapies can now be offered another chance to maintain their vision," said Dr. Michael Stur, professor at the Medical University ...

and more » 

New data among 200 LucentisR abstracts at ARVO show low number of injections ... 
Reuters
Lucentis ARVO highlights include: The RESTORE extension study: In RESTORE, patients with diabetic macular edema (DME) were treated with Lucentis 0.5 mg (monotherapy or combined with laser) or laser alone for a duration of 12 months.
Novartis (NVS) Updates on Lucentis; Shows Encouraging Results in DME Patients StreetInsider.com (subscription)

all 59 news articles » 

Positive Data on Novartis' Lucentis 
Zacks.com
The data presented at the meeting highlights the benefit of individualized treatment and the drug's long-term efficacy and safety profile in patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

and more » 

Alimera - Eyeing EU Market 
RTT News
If left untreated, diabetic retinopathy can cause vision loss in two ways namely, by proliferative retinopathy and by diabetic macular edema. Diabetic macular edema, or DME, is the major cause of vision loss in people with diabetic retinopathy.
DME implant receives Austrian marketing OK ModernMedicine

all 3 news articles » 

Aerpio Appoints Dr. Adrienne Graves to Board of Directors 
MarketWatch (press release)
"This experience, combined with her expertise in clinical trial design, will prove valuable to Aerpio as we recently completed a Phase 1 trial of AKB-9778 for the treatment of diabetic macular edema and expect to initiate a Phase 1b/2a study in this ...

and more » 

pSivida gets UK nod for behind-the-eye treatment 
FierceDrugDelivery
More good news for pSivida ($PSDV): The company's behind-the-eye macular edema treatment, Iluvien, picked up another approval, this time from the UK's Medicines and Healthcare products Regulatory Agency. The treatment uses the company's Durasert ...
pSivida Corp. Reports Results for the Third Quarter Ended March 31, 2012 MarketWatch (press release)

all 3 news articles »